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Introduction: With the development of increasing numbers of potential therapeutic agents in inflammatory
disease comes the need for effective biomarkers to help screen for drug efficacy and optimal dosing regimens
early in the clinical trial process. This need has been recognized by the Outcome Measures in Rheumatology
Clinical Trials (OMERACT) group, which has established guidelines for biomarker validation. To seek a candidate
synovial biomarker of treatment response in psoriatic arthritis (PsA), we determined whether changes in
immunohistochemical markers of synovial inflammation correlate with changes in disease activity scores assessing
28 joints (ΔDAS28) or magnetic resonance imaging synovitis scores (ΔMRI) in patients with PsA treated with a
biologic agent.
Methods: Twenty-five consecutive patients with PsA underwent arthroscopic synovial biopsies and MRI scans of an
inflamed knee joint at baseline and 12 weeks after starting treatment with either anakinra (first 10 patients) or
etanercept (subsequent 15 patients) in two sequential studies of identical design. DAS28 scores were measured at
both time points. Immunohistochemical staining for CD3, CD68 and Factor VIII (FVIII) was performed on synovial
samples and scored by digital image analysis (DIA). MRI scans performed at baseline and at 12 weeks were scored
for synovitis semi-quantitatively. The ΔDAS28 of the European League Against Rheumatism good response
definition (>1.2) was chosen to divide patients into responder and non-responder groups. Differences between
groups (Mann Whitney U test) and correlations between ΔDAS28 with change in immunohistochemical and MRI
synovitis scores (Spearman’s rho test) were calculated.
Results: Paired synovial samples and MRI scans were available for 21 patients (8 anakinra, 13 etanercept) and 23
patients (8 anakinra, 15 etanercept) respectively. Change in CD3 (ΔCD3) and CD68 expression in the synovial
sublining layer (ΔCD68sl) was significantly greater in the disease responders compared to non-responders following
treatment (P = 0.005 and 0.013 respectively). ΔCD3, but not ΔCD68 or ΔFVIII, correlated with both ΔDAS28 (r = 0.49,
P = 0.025) and ΔMRI (r = 0.58, P = 0.009).
Conclusions: The correlation of ΔCD3 with ΔDAS28 and ΔMRI following biologic treatment in this cohort
contributes to the validation of ΔCD3 as a synovial biomarker of disease response in PsA, and supports the further
evaluation of ΔCD3 for predictive properties of future clinical outcomes.
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Psoriatic arthritis is a chronic and debilitating inflamma-
tory arthropathy. It accounts for 15% of referrals to early
arthritis clinics, and has considerable morbidity [1]. The
Outcome Measures in Rheumatology Clinical Trials
(OMERACT) PsA working group has identified a hierar-
chy of domains to be included in PsA clinical trials [2],
which includes tissue analysis and magnetic resonance
imaging (MRI) in the outer domain, on the research
agenda. Utilizing these two domains, we have sought a
potential synovial biomarker of treatment response in
PsA. A biomarker is defined as a characteristic that is
objectively measured and evaluated as an indicator of a
normal biologic process, a pathophysiologic process, or a
pharmacological response to therapeutic intervention [3].
It has already been established in rheumatoid arthritis
(RA) that the mean change in DAS28 correlates with
the mean change in synovial sublining CD68 expression
across several RA patient cohorts receiving different
therapeutic agents [4-7]. Few studies have correlated
clinical composite scores with changes in PsA synovial
cell populations however. One of the reasons for this is
that no composite score has yet been validated in PsA,
although such work is currently in progress [8]. DAS28,
a score validated in RA [9], has proven to be a highly
effective tool in previous studies of PsA and biologic
agents [10-12] and is suitable for studies involving syno-
vial tissue analysis as it focuses on articular involvement.
In the synovial tissue of our patient cohort, we mea-
sured the expression of CD68, a macrophage marker,
given the clinical correlations found in RA; FVIII, an
endothelial cell marker, due to the hypervascularity and
vessel tortuosity evident in inflammed PsA synovium
compared to that of RA [13-16]; and CD3, a T-cell mar-
ker. Importantly, a previously published study which uti-
l i z e dD A S 2 8f o u n das i g n i f i c a n tc o r r e l a t i o nb e t w e e n
ΔDAS28 and ΔCD3 in the synovium of patients with
PsA after adalimumab treatment [12]. Should this find-
ing prove reproducible, particularly if different therapeu-
tic agents are used, ΔCD3 may meet the discrimination
criterion of the OMERACT biomarker validation filter
[17] and the exploration of ΔCD3 as a predictive bio-
marker of future treatment response in PsA would be
supported. ΔCD3 could be used to determine the poten-
tial efficacy of new therapeutic agents in PsA at an early
stage, as is already happening in RA clinical trials of
novel therapeutic compounds, where synovial sublining
ΔCD68 measurements are being observed to reflect clin-
ical response [18,19].
While MRI has been used to highlight the importance
of bone marrow oedema and entheseal sites of inflam-
mation in PsA [20,21], to date there have been no stu-
dies comparing histological change with quantified
synovitis by dynamic or static MRI. In this study we
examine the relationship between clinical scores and
both immunohistochemical (IHC) and MRI measures of
synovitis following biologic treatment in PsA to help
identify a potential biomarker of treatment response.
Materials and methods
Study protocol
Twenty-five patients who met the CASPAR classification
criteria for PsA [22] were enrolled in two sequential stu-
dies of identical design. The first 10 consecutive patients
received anakinra, an IL-1 receptor antagonist, 100 mg
by subcutaneous injection (SC) daily, followed by 15
consecutive patients who received etanercept, a TNF
receptor antagonist, 25 mg twice weekly SC. Both were
12-week, single centre, open-label studies undertaken at
St. Vincents University Hospital, Dublin. Ethical
approval was obtained by the hospital’s ethics committee
a n dw r i t t e ni n f o r m e dc o n s e n tw a sp r o v i d e db ya l l
patients. At the time of enrolment, each patient had to
have a diagnosis of PsA for at least three months, and at
least three tender and three swollen joints (one of which
was a knee), of a 68-joint assessment,.
Clinical parameters were measured at weeks 0 and 12,
including 28 and 68 tender (TJC) and 28 and 66 swollen
joint counts (SJC), patient pain and disease 0 to 100
mm visual analogue scale (VAS) and the Health Assess-
ment Questionnaire (HAQ). Serum erythrocyte sedi-
mentation rate (ESR) (Test-1, Ali Sax) and C-reactive
protein (CRP) levels (nephelometry) were also measured.
A DAS28 score was calculated at each time point. To
look for changes in cell marker expression and MRI
synovitis scores reflecting change in clinical activity, the
c h a n g ei nD A S 2 8o ft h eE U L A Rd e f i n i t i o no fg o o d
response (>1.2) [23] was chosen to divide the cohort
into two groups, labelled here as responders (ΔDAS28
>1.2) and non-responders (ΔDAS28 ≤1.2).
To compare the single joint MRI synovitis scores with a
single joint clinical measure, a more detailed clinical
assessment was performed of each patient’si n v o l v e d
knee. It was scored in the manner of the first published
study of PsA and a biologic agent in which pain and swel-
ling were evaluated separately on a scale of 0 to 3, where
0 represents the absence of pain or swelling [24]. The
sum of these is the final score for a given joint, which will
range from 0 to 6. A patient was defined as a knee
responder in this study if there was a reduction in their
involved knee score following treatment at Week 12.
Patients were excluded if they had received a biologic
agent within 12 weeks, cyclosporin or leflunomide within
8 weeks, or methotrexate or sulfasalazine within 4 weeks
of enrolment into the study. Patients taking ≥10 mg of
prednisolone or those who had a prednisolone dose
change within four weeks of study Day 1 were also
excluded, as were those who were pregnant, breastfeeding,
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or a history of cancer within five years of the study’s com-
mencement. Prior to receiving etanercept, patients were
screened for latent tuberculosis with a chest X-ray and
Mantoux test.
Arthroscopy
Arthroscopy and synovial biopsy of the involved knee
joint was performed at two time points (weeks 0 and
12), with a Storz arthroscope and 1.5 mm grasping for-
ceps. Biopsy samples were obtained from all knee joint
compartments, embedded in TissueTek OCT compound
(Sakura, Alphen aan den Rijn, Netherlands) and stored
in liquid nitrogen. In the majority of cases, six individual
biopsies were included together in one OCT mould for
cutting and analysis. Seven μm thick sections were cut
using a cryostat, placed on glass slides coated with 2%
3-amino-propyl-triethoxy-silane (Sigma-Aldrich Ireland
Ltd, Dublin, Ireland) and dried overnight at room tem-
perature. Sections were stored at -80°C until required
for staining.
Immunohistochemistry
A routine three-stage immunoperoxidase labeling tech-
nique was used. Tissue sections were allowed to reach
room temperature, were fixed in acetone for 10 minutes
and then air-dried. The remaining steps were performed
in an autostainer using reagents from an Envision+ sys-
tem-HRP (AEC) kit (Dako, Glostrup, Denmark). Follow-
ing quenching of endogenous peroxidase activity, the
synovial sections were incubated with mouse monoclo-
nal antibodies against cell specific markers CD3, CD68,
and FVIII (Dako, Glostrup, Denmark) for 30 minutes.
Incubation with a labelled polymer-HRP anti-mouse
antibody followed, and colour was then developed with
amino-ethylcarbazole (AEC). Slides were counterstained
with Mayer’s haematoxylin (BDH Laboratories, Poole,
UK) and mounted.
Digital image analysis
All slides were randomly assigned code numbers for
analysis and only tissue samples with a clearly identifi-
able intimal lining layer were included. All analysis was
undertaken by EKP. Eighteen high power images were
taken per slide for each of the three cell specific markers
stained. In the case of CD68, the intimal lining layer was
highlighted manually per image, such that staining could
be quantified in two areas - the intimal lining (ll) and
synovial sublining (sl) layers. Analysis was performed
using the Qwin analysis system (Leica, Cambridge, UK)
as has been previously described [25,26]. Results are
expressed as the number of positively stained cells/mm
2
of tissue for CD3 and CD68, and by integrated optical
density (IOD)/mm
2 for FVIII. The average value over all
six biopsies per patient per time point was used for
analysis.
MRI
An MRI scan of the same involved knee was performed
for each patient the day prior to arthroscopy at weeks 0
and 12, using a 1.5T Signa Excite HD MRI scanner
(General Electric Healthcare, Chalfont St Giles, Buckin-
ghamshire, UK) and a dedicated eight channel array HD
knee surface coil with patients lying supine. The exami-
nations performed included intravenous contrast
enhanced (Gadoteric acid, Dotarem, 0.5 mmol/mL,
Guerbet Laboratories, Birmi n g h a m ,U K ) ;1 0m l si na l l
examinations by slow hand injection) T1-weighted fat
suppressed pulse sequences in coronal, sagittal and axial
planes. Scanning parameters were as follows: coronal,
TR 640 ms; TE 16; slice thickness 4/1 mm; FOV 18;
NEX 2; matrix 512 × 256; sagittal, TR 500; TE 16; slice
thickness 4/1 mm; FOV 22; NEX 2; matrix 256 × 192
axial, TR 440; TE 11; slice thickness 3/1.5 mm; FOV 16;
NEX 3; matrix 224 × 192.
Once complete, the scans were arranged into pairs of
pre- and post-treatment images for each patient. These
were scored semi-quantitatively by one consultant radi-
ologist with a special interest in musculoskeletal radiol-
ogy who was blind to patient identity and scan
chronology. Each knee was divided into four anatomical
regions (medial and lateral parapateller recesses, inter-
condylar notch and suprapatellar pouch) and a synovitis
score ranging from 0 to 3 was assigned to each region
(0 = normal synovium, 1 = diffuse, even thickening, 2 =
nodular thickening, 3 = gross, nodular thickening) based
on the overall impression of the severity of synovial
abnormality in the three orthogonal scanning planes.
This method has been described and validated for syno-
vitis in knee osteoarthritis by Rhodes et al. [27]. The
regional scores were added for a final synovitis score per
knee ranging from 0 to 12.
Statistical analysis
Data was analysed with SPSS 12.0.1 for Windows (SPSS
Inc, IBM, Chicago, Illinois, USA). Change in clinical
parameters, IHC markers and MRI synovitis scores fol-
lowing treatment were evaluated using the Wilcoxon
signed rank test and differences between responder and
non-responder groups were determined with the Mann
Whitney U test. Correlations between ΔDAS28 with
change in IHC and MRI synovitis scores were calculated
using Spearman’s rho test.
Results
Twenty-five patients completed at least one of the IHC
or MRI components of these studies (19 completed all
components), and were, therefore, included for clinical
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and 66.6% female, had a mean age (range) of 43.2
(27 to 60) and 48.7 (26 to 64) years and a mean disease
duration of 9.1 (1 to 42) and 7.5 (1 to 29) years in the
anakinra and etanercept treated cohorts, respectively.
Four patients had oligoarthritis (≤4 involved joints) at
enrolment (all etanercept treated); the remaining 21
patients had polyarticular disease (mean SJC66 17, SD
9.2, range 6 to 43).
Five of the anakinra patients (50%) and 11 of the eta-
nercept patients (73.3%) were taking a non-steroidal
anti-inflammatory drug (NSAID), 2 and 4 of whom were
also on a stable dose of prednisolone ≤10 mg.
Clinical responses
Changes in clinical parameters following treatment are
s h o w ni nT a b l e1 .I nb o t hstudies, the DAS28 was
reduced significantly after treatment; the changes were
more pronounced in the etanercept group compared to
the anakinra group. Nineteen of the 25 patients achieved
an improvement in DAS28 of >1.2 and are labelled
responders (5 anakinra and 14 etanercept), and 6
patients did not and are labelled non-responders (5 ana-
kinra, 1 etanercept).
Twenty-three patients had involved knee scores avail-
able. There was a significant difference between the
knee scores of the knee responders (n = 16, 8 anakinra,
8 etanercept) at Week 0 and Week 12 (3 (1 to 6) and 1
(0 to 4) respectively, median (range), P = 0.00), and not
between the non-responders (n = 7, 2 anakinra, 5 eta-
nercept), (2 (2 to 3) and 3 (2 to 4) respectively, P = 0.1).
Immunohistochemistry
Synovial biopsies at baseline and 12 weeks were avail-
able for 21 patients (8 anakinra, 13 etanercept).
Combining the total patient cohort, there was a signif-
icant reduction in CD3 expression following treatment
in the responder group (28 (1 to 1,344) at Week 0 to
17.5 (0.5 to 734) at Week 12, P = 0.026, median
(range)), but not in the non-responder group (68 (13 to
265) at Week 0 and 217 (14 to 389) at Week 12, P =
0.080) (Figure 1A). A reduction in expression was not
observed for any of the other cell markers following
treatment in either the responder or non-responder
groups. Of interest, however, there was a significant
increase in CD68sl expression in the non-responder
group at Week 12 (1,835 (1 667 to 2,218)) compared to
Week 0 (1,409 (494 to 1,795)), (P = 0.043).
T h ed e g r e eo fc h a n g ei nc e l lm a r k e re x p r e s s i o nf o l -
lowing treatment was significantly greater for ΔCD3 in
the group of responders (19 (-100 to 1,031)) than the
non-responders (-109.3 (-376 to 3)), P = 0.005, (Figure
1C). This was also the case for ΔCD68sl (-53 (-1,336 to
2,178)) among the responders compared to the non-
responders (-382 (-1,247 to -127)), P = 0.013.
Looking at the individual treatment groups separately,
there was a significant reduction in CD3 expression in
the etanercept treated responders at Week 12 (n = 16),
but not CD68sl, CD68ll or FVIII (Figure 1B and Table 2).
In the anakinra treated patients, there was no change
within the responder group in CD3 expression, but there
was a non-significant increase in the non-responder
group following treatment.
MRI
Paired baseline and 12-week scans were available for 23
patients (8 anakinra, 15 etanercept).
There was no change in MRI detected synovitis fol-
lowing treatment in the combined cohort of responders
(5 (4 to 12) at Week 0 to 5 (2 to 11) at Week 12, P =
0.1) or non-responders (3.5 (0 to 11) to 4 (1 to 7), P =
0.79). Likewise, there was no difference in the change in
MRI synovitis scores following treatment between the
responder and non-responder groups (0 (-3 to 6) and 1
(-7 to 7) respectively, P = 0.83). Individually, neither eta-
nercept nor anakinra treatment led to a significant
Table 1 Clinical parameters of patients with PsA at baseline and 12 weeks following treatment
Anakinra n = 10 Etanercept n = 15
Week 0 Week 12 P-value Week 0 Week 12 P-value
TJC28 9.5 (3 to 19) 7 (1 to 13) 0.033 11 (1 to 25) 2 (0 to 28) 0.004
TJC68 24.5 (9 to 52) 13.5 (3 to 35) 0.015 15 (3 to 57) 3 (0 to 38) 0.002
SJC28 8 (1 to 18) 5 (0 to 8) 0.032 4 (1 to 21) 1 (0 to 8) 0.005
SJC68 20.5 (6 to 27) 8 (0 to 23) 0.028 9 (3 to 43) 2 (0 to 16) 0.007
ESR 18.5 (3 to 79) 7.5 (2 to 46) 0.059 14 (4 to 91) 5 (1 to 26) 0.001
CRP 17 (4 to 70) 7.5 (0 to 29) 0.044 7 (0 to 42) 0 (0 to 18) 0.092
d VAS 66 (27 to 85) 47 (12 to 70) 0.051 44.5 (5 to 93) 15 (2 to 56) 0.002
p VAS 65.5 (21 to 91) 46.5 (20 to 75) 0.169 50 (22 to 93) 12 (2 to 66) 0.001
HAQ 1.25 (0.75 to 2.38) 1.13 (0.25 to 1.88) 0.057 1.13 (0 to 2.5) 0.25 (0 to 2.25) 0.01
DAS28 5.03 (3.77 to 7.16) 4.17 (2.35 to 5.98) 0.022 5.26 (3.08 to 6.95) 2.01 (0.14 to 5.35) 0.001
Median (range). d VAS, disease visual analogue scale; p VAS, pain visual analogue scale.
Pontifex et al. Arthritis Research & Therapy 2011, 13:R7
http://arthritis-research.com/content/13/1/R7
Page 4 of 10Figure 1 ΔCD3 of combined responders and non-responders (A), etanercept responders (B). and ΔCD3 of combined responders versus
non-responders (C).
Table 2 Change in cell marker expression following treatment in the responder and non-responder groups
Week 0 Week 12 P-value
CD3 etanercept R n = 12 27.5 (6.5 to 1121) 16 (0.5 to 113) 0.05*
NR n = 1 17 14 n/a
anakinra R n = 4 33.5 (1 to 1344) 32.9 (3 to 734) 0.47
NR n = 4 87.9 (13 to 265) 300 (166 to 389) 0.068
CD68sl etanercept R n = 12 127 (138 to 3,543) 712 (112 to 2,318) 0.31
NR n = 1 1,408 1,667 n/a
anakinra R n = 4 1,370 (362 to 2,685) 1,444 (453 to 2,414) 0.72
NR n = 4 1,431 (494 to 1,795) 1,879 (1,741 to 2,218) 0.068
CD68ll etanercept R n = 12 226 (38 to 513) 213 (17 to 466) 0.48
NR n = 1 191 150 n/a
anakinra R n = 4 174 (129 to 469) 214 (154 to 473) 0.47
NR n = 4 159 (108 to 197) 147 (104 to 319) 0.72
FVlll etanercept R n = 11 132,242 (43,272 to 754,550) 139,294 (51,817 to 439,712) 0.53
NR n = 1 58,525 142,834 n/a
anakinra R n = 4 218,619 (88,372 to 353,725) 280,785 (226,415 to 353,725) 0.27
NR n = 4 286,939 (84,419 to 521,103) 437,447 (184,155 to 545,675) 0.72
MRI etanercept R n = 13 8 (4 to 12) 5 (2 to 11) 0.12
NR n = 1 3 1 n/a
anakinra R n = 5 4 (4 to 12) 4 (4 to 9) 0.66
NR n = 3 4 (0 to 11) 4 (4 to 7) 1
Median (range). n/a, not applicable; NR, non-responder; R, responder.
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der or non-responder groups (Table 2).
Looking specifically at the knee responders, there was
a significant difference in the MRI synovitis scores of
the knee responders (n = 15) at Week 0 compared to
Week 12 (6 (4 to 12) and 4 (2 to 11), P = 0.049), but
not of the knee non-responders (n = 5), (4 (0 to 8) and
4 (1 to 7), P = 1.0).
Associations between ΔCD3, ΔDAS28 and ΔMRI
The primary aim of this study was not to compare the
clinical efficacy or specific effects on the synovium of
two different biologic agents, but to seek a candidate
biomarker of disease response. Change in this biomarker
should correlate with change in disease activity and be
irrespective of the type of therapeutic intervention used.
All patient data were combined, therefore, to determine
correlations between change in DAS28 with change in
IHC and MRI synovitis scores, as has been done in pre-
vious similar studies [12,28].
ΔCD3 expression correlated significantly with
ΔDAS28 following treatment (r = 0.49, P =0 . 0 2 5 ) ,
(Table 3). No correlations were observed between
ΔDAS28 or any of its individual components, and
change in expression of the other IHC markers. Figure 2
shows representative images of synovial CD3 expression
at baseline and 12 weeks for two patients with differing
clinical responses. Patient 1 (etanercept) achieved a
ΔDAS28 of 1.22 and ΔCD3 of 19, and Patient 2 (ana-
kinra) achieved a ΔDAS28 of 0.16 and ΔCD3 of -118.
There was a significant correlation between ΔCD3 and
ΔMRI synovitis following treatment (r = 0.58, P = 0.009),
(Table 3). Furthermore, MRI synovitis and CD3 expression
measured at all time points correlated significantly (r =
0.504, P = 0.001), (n = 38). ΔMRI did not correlate with
change in expression of the other IHC markers or with
ΔDAS28 scores (r = -0.027, P =0 . 9 1 ) .F i g u r e3s h o w s
representative images of CD3 stained synovium and corre-
sponding MRI scans of a patient who had a ΔDAS28 of
2.54, a ΔCD3 score of 287 and a ΔMRI synovitis score of 4.
Discussion
This study has demonstrated that change in synovial
CD3+ T-cell expression correlates with both ΔDAS28
and ΔMRI synovitis scores in a cohort of patients with
PsA treated with either anakinra or etanercept.
Over the last 15 years, some fundamental features of
the spondyloarthropathy (SpA) synovium have been elu-
cidated. First, the inflamed synovium of SpA appears to
differ histologically from that of RA [13-16,29]. Second,
the synovial histology of subtypes of SpA, including oli-
goarticular versus polyarticular PsA, have been shown to
be similar [16,29,30]. Third, there are histological
changes in the synovium when patients with SpA
Table 3 Correlation of ΔDAS28 and ΔMRI synovitis scores
with cell marker expression following biologic treatment
ΔCD3 ΔCD68 sl ΔCD68 ll ΔFVIII
ΔDAS28 0.49 (0.025*) 0.27 (0.24) -0.07 (0.77) 0.244 (0.30)
ΔMRI 0.58 (0.009*) 0.22 (0.378) 0.07 (0.78) 0.33 (0.18)
Correlation coefficient (P =). N = 21 for all IHC groups except FVIII (n = 20)
and n = 19 for all MRI groups; ll, lining layer; sl, sublining layer.
Figure 2 Synovial images showing CD3 expression in a DAS28
moderate responder (Patient 1) and non-responder (Patient 2).
A and B are baseline and Week 12 images of Patient 1, and C and
D are baseline and Week 12 images of Patient 2 respectively.
Figure 3 B a s e l i n e( A )a n dW e e k1 2( B )M R Is c a n sw i t h
corresponding baseline (C) and Week 12 (D) CD3 stained
synovium (red-brown). Thickened enhanced synovium (* in A) has
improved following treatment.
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therapy in SpA have shown a significant reduction in
polymorphonuclear (PMN) cells, CD4+ and CD8+ T
cells and macrophage subsets after 12 weeks, plus a
trend toward reduced CD3+ T cell numbers [31,32].
Exclusively in PsA, reduction in T cell and sublining
macrophage infiltration has been observed as early as 48
hours after an infliximab infusion [33] and also follow-
ing treatment with alefacept and methotrexate [34,35].
Correlations with clinical outcomes were not performed
in these studies. Consistent with our etanercept respon-
ders, in a cohort of PsA patients treated with adalimu-
mab, a significant reduction in the number of CD3
positive cells was observed after four weeks [12]. The
number of CD68+ cells in the synovial sublining did
decrease in the responders of both latter studies, but
not significantly, while CD68sl expression in this current
study’s non-responders significantly increased. Thus, in
PsA, change in synovial CD3 cell infiltration, and not
CD68, appears to be a superior biomarker of treatment
response. Reduction in angiogenesis has been demon-
strated in PsA patients after infliximab treatment
[36,37], but was not found after etanercept treatment in
the present study, and may be related to the difference
in mechanism of action between the anti-TNF antibo-
dies compared to etanercept [38].
Only two previously published trials of SpA synovium
have measured DAS28 scores. Of 52 SpA patients who
may have received infliximab, etanercept or no biologic
treatment, DAS28 scores were calculated for 28 patients
who had polyarticular disease [28]. These scores corre-
lated only with change in CD163 expression, a macro-
phage subset marker, in the lining layer, and not with
change in CD3 or CD68 expression in the sublining
layer. The patients with PsA were not evaluated as a dis-
tinct group. Only one other trial, which used adalimu-
mab or placebo, has exclusively enrolled PsA patients
and used DAS28 as a primary clinical outcome measure
[12]. Consistent with our results, that study also demon-
strated a significant correlation between ΔCD3 and
ΔDAS28. Taking these two papers together, four differ-
ent agents have now been used in two PsA cohorts
(anakinra/etanercept and adalimumab/placebo) and both
studies have found this proportional relationship
between ΔCD3 and ΔDAS28.
While not conclusive, the findings in this study are also
consistent with the hypothesis that T-cells play an active
role in PsA pathogenesis. Large numbers of T cells are
present in the PsA synovium, synovial fluid and subchon-
dral bone beneath the entheses [13,29,39], where bone
oedema and erosions can occur. Th1 derived cytokines
dominate in the PsA synovium [35,40] and the CD8+ cell
population contains T cell repertoires which are oligo-
clonally expanded [41]. The association of PsA with
human leukocyte antigen (HLA) Class 1 [42], the devel-
opment of Ps and PsA as a manifestation of the Acquired
Immunodeficiency Syndrome (AIDS) and the transmis-
sion of PsA following bone marrow transplantation
[43,44] all suggest T-cells take part in disease expression.
Lastly, the fact that cyclosporin and ustekinumab, which
impair T-cell activation, and alefacept, which specifically
targets activated T cells, are effective in PsA, support
T-cell involvement further [45-47].
The use of MRI in PsA research has been reviewed in
detail [48], and an MRI scoring system for hands in PsA
has recently been developed by the OMERACT imaging
group [49,50]. We opted for our scoring method as it
focuses on knee synovitis and is semi-quantitative. MRI
synovitis has been shown to reduce significantly follow-
ing anti-TNF therapy in PsA [51,52], and we found this
to be the case in our combined group of clinical knee
responders. These former studies assessed mostly hand
joints as opposed to exclusively knees and used quanti-
tative analysis. Correlations of MRI findings and histo-
pathology in inflammatory arthritis are emerging in the
literature. Bollow et al. compared dynamic MRI and
sacroiliac joint immunohistochemistry [53] and found
T cells and macrophages to be the most common
inflammatory cells in active SpA sacroiliitis, although
>95% of the tissue obtained was cartilage and bone. In
severe AS, MRI-detected bone oedema has correlated
well with histological bone marrow oedema of zygoapo-
physeal joints, but less so with actual inflammatory cell
infiltrates [54]. Other studies correlating MRI findings
with synovial and bone oedema histology have been
undertaken in RA [55,56], but not yet in PsA. This is
the first study, therefore, to demonstrate a relationship
b e t w e e nM R Is y n o v i t i sa n dC D 3e x p r e s s i o ni nP s A ,
both at all time points in the study and when comparing
the changes with treatment.
No relationship was found in this cohort between
ΔMRI synovitis and ΔDAS28. The fact that this MRI
data reflects change in a single joint only, in contrast to
DAS28, and that improvement in DAS28 may or may
not involve the knee, will contribute to this. The stron-
gest correlation being between ΔCD3 expression and
ΔMRI synovitis scores is not surprising, as these origi-
nate from the same single joint and are objectively mea-
sured, excluding any subjectivity of clinical scoring and
additional pathologies that could influence single joint
clinical scores.
As two patients did not undergo follow-up MRI and
three different patients did not have adequate synovial
tissue for analysis, our study is limited by some uncou-
pling of the patient groups included in IHC and MRI
analyses. Also, in three pre-treatment scans (two etaner-
cept, one anakinra), insufficient fat suppression may have
led to an underestimation of the degree of synovitis.
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Page 7 of 10Conclusions
This study demonstrates a significant correlation between
synovial ΔCD3 expression and ΔDAS28, and synovial
ΔCD3 expression and ΔMRI synovitis scores in a cohort
of 25 patients with PsA treated with either anakinra or
etanercept. The establishment of ΔCD3 as a candidate
biomarker of treatment response in PsA should prompt
other studies using different therapeutic agents to rein-
force this concept, and also to determine its ability to
predict future clinical outcomes. Further work focusing
on changes in peripheral blood T-cell subsets for a more
easily accessible biomarker could prove useful.
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